Top Markets
Coin of the day
Actuate Therapeutics Inc Actuate Therapeutics Inc

Actuate Therapeutics Inc

ACTU
Rang in Aktien #28698
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the... Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Aktienkurs
$1.05
Marktkapitalisierung
$25.12M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-86.83%
Land
US
Handel Actuate Therapeutics Inc (ACTU)

Kategorie

Kursverlauf für Actuate Therapeutics Inc (ACTU)
Höchster Schlusskurs: $1.04 am 2026-08-01

Niedrigster Schlusskurs: $8.39 am 2024-08-01
Kursverlauf der Aktie von Actuate Therapeutics Inc von 2024 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -36.39%
2025 -14.02%
2024 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$552.07 41.28%
US
$168.77 504.69%
US
$1.03K 57.19%
NL
$117.42 -19.34%
AU
$753.28 8.59%
CH